Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard

Regulatory Toxicology and Pharmacology

Volumn 32, Issue 2, 2000, Pages 135-143

  Silva Lima, Beatriz ^a   Van der Laan, Jan Willem ^b  

^a UNIVERSITY OF LISBON   (Portugal)

^b MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

Carcinogenesis; Nongenotoxic mechanisms; Safety assessment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANXIOLYTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ANTAGONIST; CARCINOGEN; DNA BINDING PROTEIN; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GONADORELIN DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYPNOTIC SEDATIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN TYROSINE KINASE;

ARTICLE; CARCINOGENESIS; CYTOTOXICITY; GENE EXPRESSION; GENOTOXICITY; HEALTH HAZARD; PRIORITY JOURNAL; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TOXICOLOGY;

RODENTIA;

EID: 0033742687     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.2000.1427     Document Type: Article

References (42)

1. Reversibility of renal cortical lesions induced in rats by high doses of nitriloacetate in chronic feeding studies
2. Growth factors and cancer
3. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP
4. Prevalence of genotoxic chemicals among animal and human carcinogenic agents evaluated in the IARC monograph series
5. Hepatic peroxisome proliferation in rodents and its significance for humans
6. Rodent carcinogenicity bioassay: Past, present and future
7. Genotoxicity studies of peroxisome proliferators
8. Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential
9. Mechanisms of hormone-mediated carcinogenesis of the ovary in mice
10. Genetic errors, cell proliferation and carcinogenesis
11. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals
12. Possible mechanisms in hepatocarcinogenesis by the peroxisome proliferator di(2-ethylhexyl)phatalate
13. Growth factor second messenger systems: Oncogenes and the heterotrimeric GTP-binding protein connection
14. Marketed human pharmaceuticals reported to be tumorigenic in rodents
15. Preneoplastic lesions in rodent kidney induced spontaneously or by non-genotoxic agents: Predictive nature and comparison to lesions induced by genotoxic carcinogens
16. Markers of non-genotoxic carcinogenesis. 4. F344 rat thyroid
17. Ethyl acrilate-induced gastric toxicity. III. Development and recovery of lesions
18. An empirical examination of factors influencing prediction of carcinogenic hazard across species
19. Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: Their rate of onset and their reversibility
20. Study of liver enzymes: Peroxisome proliferation and tumor rates in rats at the end of carcinogenicity studies with benzafibrate and clofibrate
21. Adenocarcinoma of the vagina in adolescence: A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas)
22. Clear-cell adenocarcinoma of the genital tract in young females: Registry report
23. Pathological changes in female C3H mice continuously fed diets containing diethylstilbestrol or 17b-estradiol
24. Evaluation of the carcinogenic risk of chemicals to humans: Chemicals, industrial processes and industries associated with cancer in humans
25. Mechanism of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals
26. Biochemical mechanisms of induction of hepatic peroxisome proliferation
27. Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment
28. Chemicals classified by the IARC: An investigation of some of their toxicological characteristics
29. Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis
30. Clear-cell adenocarcinoma of the cervix after maternal treatment with synthetic estrogens
31. Highlights in the history of saccharin toxicology
32. Carcinomas of the uterine cervix and vagina in estrogen- and androgen-treated hybrid mice
33. The molecular biology of carcinogenesis
34. The role of receptors in multistage carcinogenesis
35. Time and dose study on the response of rats to the hypolipidaemic drug fenofibrate
36. Current knowledge of mechanisms of carcinogenicity: Genotoxins versus non-genotoxins
37. Current knowledge of mechanisms of carcinogenicity: Genotoxins versus non-genotoxins
38. Oxidative DNA damage caused by persistent peroxisome proliferation: Its role in hepatocarcinogenesis
39. Stratification of rodent carcinogenicity bioassay results to relect relative human hazard
40. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe
41. 17b-Oestradiol and enovid mammary tumorigenesis in C3H/HeJ female mice: Counteraction by concurrent 2-bromo-a-ergocryptine
42. Growth factor receptor tyrosine kinases